Teleflex (NYSE:TFX) Shares Cross Above 200 Day Moving Average – Here’s Why

Teleflex Incorporated (NYSE:TFX)’s share price passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $130.62 and traded as high as $132.21. Teleflex shares last traded at $130.4750, with a volume of 400,446 shares trading hands.

Wall Street Analysts Forecast Growth

TFX has been the topic of a number of research reports. Wall Street Zen upgraded Teleflex from a “sell” rating to a “hold” rating in a report on Sunday, August 9th. Piper Sandler reissued an “overweight” rating and set a $169.00 target price (up from $160.00) on shares of Teleflex in a research report on Friday, August 7th. Truist Financial cut their price objective on Teleflex from $150.00 to $142.00 and set a “hold” rating for the company in a research report on Wednesday, October 14th. Bank of America raised Teleflex from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $158.00 in a research report on Monday, September 28th. Finally, Zacks Research raised shares of Teleflex from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.40.

Teleflex Price Performance

The firm has a market cap of $5.78 billion, a price-to-earnings ratio of -5.86, a PEG ratio of 0.87 and a beta of 0.83. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. The company’s fifty day moving average is $130.95 and its 200 day moving average is $130.76.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.28 by $0.48. The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The company’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, equities research analysts predict that Teleflex Incorporated will post 7.22 EPS for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th were given a $0.34 dividend. The ex-dividend date was Friday, August 14th. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s payout ratio is presently -5.84%.

Institutional Trading of Teleflex

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kelleher Financial Advisors bought a new stake in shares of Teleflex in the second quarter worth $25,000. Root Financial Partners LLC purchased a new stake in shares of Teleflex in the third quarter worth approximately $27,000. Allworth Financial LP bought a new stake in shares of Teleflex in the 2nd quarter worth $44,000. Versant Capital Management Inc boosted its stake in shares of Teleflex by 573.4% in the 2nd quarter. Versant Capital Management Inc now owns 431 shares of the medical technology company’s stock worth $55,000 after buying an additional 367 shares during the last quarter. Finally, Trust Co. of Vermont bought a new position in shares of Teleflex during the 2nd quarter valued at approximately $57,000. 95.62% of the stock is currently owned by institutional investors.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.